Friday, January 9, 2009
pehel.com
Home Latest News Pakistan World Science / Technology Sports Entertainment Health Business


Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years
Source: Medical News Today E-Mail this News Story to a friend E-Mail this Story
Category: Health
Publication Date: Mon, 13 Oct 2008 04:00:00 PDT
News URL: http://www.medicalnewstoday.com/articles/125275.php
Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two YearsOf those treated with the Endeavor® Resolute drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT), in the RESOLUTE IDE trial only two patients required repeat procedures - a remarkably low 1.5 percent rate of target lesion revascularization (TLR) - at two years following implant, according to data released today at the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
Click here for full Story
http://www.medicalnewstoday.com/articles/125275.php
Bookmark this news story online:
Add Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to BlinkListAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to DeliciousAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to DiggAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to FarkAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to FurlAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to BlogarithmAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to MeneameAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to My Yahoo!Add Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to ReddItAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to ShadowsAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to SimpyAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to SpurlAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Sync2ItAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to MagnoliaAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to NewsVineAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Ask Jeeves
Add Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Raw SugarAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to DiigoAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to NetVouzAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Stumble UponAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to SegnaloAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Google BookmarksAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Microsoft LiveAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to BlogMarksAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to WinkAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to TechnoratiAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Feed Me LinksAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to LinkaGoGoAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to BlueDotAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Mister WongAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to TailRankAdd Medtronic's Third-Generation Endeavor® Resolute Drug-Eluting Stent Maintains Strong Efficacy And Safety Profile At Two Years to Yahoo Bookmarks

Comments

No comments found... be the first one to comment on this story :)

Post a Comment
Name:
   
E-Mail Address:
   
Website / Blog URL (optional):
   
Comments:
   
Security Code:
   
  
   By submitting these comments, you are agreeing to our Terms of Service
    
Latest News
Latest News World News Pakistan News Technology News Entertainment News Business News Sports News
bullet Perfectionist Protein-Maker Trashes Errors
bullet Unibioscreen Announces Progress Of Phase I Clinical Trial For UNBS1450 In Europe In Cancer Patients With Advanced Solid Tumors
bullet Excessive Use Of Antiviral Drugs Could Aid Deadly Flu According To Study
bullet Don't Let 'iPatient' Detract From Hands-On Medicine, Stanford Author/Educator Urges
bullet Absence Of CLP Protein Can Be Indicative Of Oral Cancer
bullet U.S. Patent And Trademark Office Accepts Pfizer's Reissue Application On Lipitor Enantiomer Patent
bullet Target Discovered That Could Ease Spinal Muscular Atrophy Symptoms
bullet BASi Receives A European Patent For Culex(R)
bullet Winter Babies Face Socioeconomic Disadvantages
bullet Xenomics, Inc. Discusses HPV Screening Test Based On Transrenal DNA Technology At 52nd All India Congress Of Obstetrics & Gynecology
bullet Court Rules In Favor Of Medtronic In Fidelis Litigation
bullet Human Genomics In China
bullet The MDS Foundation Says VIDAZA Approval In Europe Could Provide Survival Benefits To Patients With Myelodysplastic Syndromes And Related Cancers
bullet Initial Findings Could Lead To A New Approach For Treating Fragile X Syndrome
bullet Advaxis' Phase II Clinical Trial "HOLD" Lifted
bullet Women's Access To Donated Kidneys Declines With Age, Particularly Compared With Men
bullet Cameron Health Commences Clinical Trial Of The Minimally Invasive Totally Subcutaneous Implantable Defibrillator For Treatment Of SCA
bullet Avian Flu Becoming More Resistant To Antiviral Drugs, Says University Of Colorado Study
bullet New Test Will Catch Sports Cheats On New Endurance Drugs
bullet Mountaineers Measure Lowest Human Blood Oxygen Levels On Record
bullet HHS Issues Action Plan To Prevent Health Care-Associated Infections
bullet Health Care Delivery Could Be Adversely Affected By Cost Containment Focus
bullet QuantRx(R) Announces FDA 510(k) Clearance For Its RapidSense(R) Methamphetamine Test
bullet HWI Scientist First In World To Unravel Structure Of Key Breast Cancer Target Enzyme
bullet KineMed Awarded Michael J. Fox Foundation Funding To Validate Translational Biomarker Of Microtubule Function In Parkinson's Disease
 
© 2007 Verge Systems